N

Nykode Therapeutics ASA
OSE:NYKD

Watchlist Manager
Nykode Therapeutics ASA
OSE:NYKD
Watchlist
Price: 2.5 NOK 1.38%
Market Cap: 816.4m NOK
Section:
 

Relative Value

The Relative Value of one NYKD stock under the Base Case scenario is 0.49 NOK. Compared to the current market price of 2.5 NOK, Nykode Therapeutics ASA is Overvalued by 80%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NYKD Relative Value
Base Case
0.49 NOK
Overvaluation 80%
Relative Value
Price
N
Worst Case
Base Case
Best Case

Valuation Multiples

11.9
P/S
P/S
Price to Sales
11.9
vs History
55
vs Industry
32
Median 3Y
22.9
Median 5Y
16.8
Industry
7.9
Forward
790.6
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-7.4
Median 5Y
-7.4
Industry
23.7
Forward
-80.7
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-2.9
Median 5Y
-1.1
Industry
22
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-2.8
Median 5Y
-1.3
Industry
23.8
More Details
0.8
P/B
P/B
Price to Book Value
0.8
vs History
74
vs Industry
70
Median 3Y
1.9
Median 5Y
3.1
Industry
3.3
More Details
12
EV/S
EV/S
Enterprise Value to Sales
12
vs History
38
vs Industry
25
Median 3Y
11.6
Median 5Y
10.4
Industry
8.3
Forward
806.7
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.1
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
20
Median 3Y
-3
Median 5Y
-3
Industry
6.4
Forward
-27.8
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
18
Median 3Y
-2.8
Median 5Y
-2.8
Industry
7
Forward
-29.9
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
25
Median 3Y
-1.9
Median 5Y
0.4
Industry
8.3
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
21
Median 3Y
-1.9
Median 5Y
0.4
Industry
6.5
More Details
0.8
EV/IC
EV/IC
Enterprise Value to IC
0.8
vs History
69
vs Industry
27
Median 3Y
3.9
Median 5Y
23.7
Industry
5.7
More Details

Multiples Across Competitors

NYKD Competitors Multiples
Nykode Therapeutics ASA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
NO
Nykode Therapeutics ASA
OSE:NYKD
806.4m NOK 11.9 -7.3 -3.3 -3.1
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 809 907.8 -160 693.5 -195 133.1 -192 906.4
US
Abbvie Inc
NYSE:ABBV
394.7B USD 6.6 168.1 16.3 23.1
US
Amgen Inc
NASDAQ:AMGN
170.9B USD 4.8 24.4 17.7 17.7
US
Gilead Sciences Inc
NASDAQ:GILD
149.5B USD 5.1 18.4 12.4 12.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.8B USD 9.8 31.2 22.9 23.9
US
Epizyme Inc
F:EPE
94.1B EUR 2 083.7 -531.7 -579 -563.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.1B USD 5.5 17.1 16.2 18.4
AU
CSL Ltd
ASX:CSL
87.1B AUD 3.7 19.3 13 16.2
NL
argenx SE
XBRU:ARGX
45.9B EUR 15 35.2 60.8 62.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.4B USD 16.3 1 202.7 158 191.6
P/E Multiple
Earnings Growth PEG
NO
N
Nykode Therapeutics ASA
OSE:NYKD
Average P/E: 189.5
Negative Multiple: -7.3 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 693.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
168.1
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.4
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
18.4
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.2
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -531.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.1
9%
1.9
AU
CSL Ltd
ASX:CSL
19.3
11%
1.8
NL
argenx SE
XBRU:ARGX
35.2
40%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 202.7
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
NO
N
Nykode Therapeutics ASA
OSE:NYKD
Average EV/EBITDA: 39.7
Negative Multiple: -3.3 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 133.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
17.7
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.9
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
11%
1.5
AU
CSL Ltd
ASX:CSL
13
8%
1.6
NL
argenx SE
XBRU:ARGX
60.8
839%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
158
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
NO
N
Nykode Therapeutics ASA
OSE:NYKD
Average EV/EBIT: 45.7
Negative Multiple: -3.1 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 906.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.1
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
17.7
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.9
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.4
13%
1.4
AU
CSL Ltd
ASX:CSL
16.2
11%
1.5
NL
argenx SE
XBRU:ARGX
62.5
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
191.6
N/A N/A

See Also

Summary
NYKD intrinsic value, competitors valuation, and company profile.
DCF Valuation
NYKD stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NYKD stock valuation using valuation multiples.
Wall Street Estimates
NYKD price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NYKD stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 303,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.